Intrexon misses by $2.46, beats on revs
- Reports Q4 (Dec) loss of $2.59 per share, $2.46 worse than the single analyst estimate of ($0.13); revenues fell 43.9% year/year to $43.19 mln vs the $42.61 mln S&P Capital IQ Consensus.
- Collaboration and licensing revenues decreased $68.7 million from the year ended December 31, 2017 primarily due to (i) the mutual termination in 2017 of the Company's second ECC with Ziopharm for the treatment of graft-versus-host disease
- Based on Intrexon's financial position, including its cash, cash equivalents and short-term investments of $224 million at December 31, 2018, in connection with issuing its financial statements Intrexon expects to include a conclusion in its Form 10-K that there is substantial doubt about its ability to continue as a going concern.
No comments:
Post a Comment